ExSight Capital

About The Fund

ExSight Ventures is an early-stage venture capital firm with a focus on life sciences, specifically in the fields of ophthalmology and oncology. As a returns-oriented, mission-focused firm, ExSight primarily targets innovative diagnostic and treatment solutions within the ophthalmic sector. Established to address the lack of early-stage funding for life science companies, ExSight Ventures brings together a specialized team of two accomplished retinal surgeons and seasoned investment professionals to spearhead its efforts. Their in-depth domain expertise and extensive networks are integral to the firm's investment strategy, providing unique insights and facilitating early investments in promising ventures. ExSight Ventures' investment portfolio includes biotechnology, medical devices, pharmaceuticals, and software solutions that serve applications in eye care. By leveraging their focused expertise in ophthalmology, the firm aims to produce superior investment returns, as domain specialization has been linked to better performance outcomes. ExSight rejects the notion that generalist diversification is superior, arguing instead for diversifying across focused managers with deep domain expertise. Their approach is oriented towards capital efficiency, prioritizing investment in technology development to maximize value creation. The firm capitalizes on the eye's unique anatomical features, which allow for rapid feedback and testing of novel treatments, and the retina's suitability as a model for central nervous system research. Furthermore, ExSight Ventures recognizes powerful external factors, such as an aging global population, a surge in diabetes, and middle-class growth, which drive the need for innovations in eye care. With a commitment to invest in pre-seed to Series B rounds, ExSight ensures their investments are significant at this crucial stage. The firm's targeted investment range lies between $5,200,000 and $6,000,000. They are also active in fostering collaborations and partnerships for their portfolio companies to thrive. ExSight Ventures' investment thesis and specialized approach position them as a key player in early-stage funding within the life sciences sector, particularly in ophthalmology.